̵ Presentation of 4 products on the stand including the main product Neurophet AQUA
̵ Conduct in-depth discussions jointly with R&D team members and cooperate with multiple global companies
Seoul, South Korea, November 25, 2022 /PRNewswire/ — Neurophet, an artificial intelligence (AI) solutions company for brain disease, announced on the 25th that Neurophet will participate in the Radiological Society of North America 2022 (RSNA 2022). At this conference, Neurophet will present several AI analysis solutions for brain imaging, including Neurophet SCALE PET, which has received 510(k) clearance from the United States Food and Drug Administration (FDA).
Neurophet plans specific product demonstrations and product presentations on the stand so that on-site attendees can experience Neurophet solutions. The main products include “Neurophet AQUA” brain MRI analysis and interpretation software, “Neurophet SCALE PET” brain PET (PET tracer deposition) analysis software, electrical stimulation simulation software brain “Neurophet tES Lab” and the brain region of interest analysis research tool, “Neurophet SegPlus”.
At this conference, Neurophet will share research, both independent and joint, related to brain image analysis through digital posters and oral sessions. These exclusive studies published via online poster presentation are: A fully automated and quantifiable visual scoring system for WMH using a rule-based algorithm: the modified Fazekas scale using T2 fluid attenuated inversion recovery magnetic resonance imaging; NeuroScreener: Anomaly classifier based on Brain MR’s quantized vector embedded autoencoderI; Interaction effect of white matter hyperintensity load and cognitive state on gray matter volume: a large-scale T1 and T2 cross-sectional multimodal study using an automated segmentation tool.
Neurophet’s brain image analysis AI technology presented at this conference is expected to provide quantitative numbers for neonatal brain MRI scan results, allowing for more objective determination of newborn developmental disorders. The study will be introduced in the oral presentation for its clinical use and research on MRI analysis of neonatal brains with Neurophet. The joint research abstract is Multimodal MRI-Based Neonatal Brain Segmentation Using Deep Neural Network. Previously, in the case of newborn babies with suspected developmental disorders, brain MRI was taken and radiologists visually determined the presence or absence of abnormalities in brain development based on medical knowledge and experience.
Additionally, Neurophet neurologists will disclose research findings on the diagnosis and prognosis of brain diseases using AI-based brain image analysis technology during the AI theater presentation.
CEO Jake Junkil Been of Neurophet said, “Neurophet will share the latest research findings on brain image analysis technology prepared over the past year at RSNA, the world’s largest radiology society. He stressed, “In-depth discussions on joint R&D and cooperation will take place with several global companies so that the research results that will be presented at this conference can lead to significant commercial results.
The RSNA, founded in 1915 and celebrating its 108th anniversary this year, is the world’s largest radiology society, attracting more than 50,000 experts and leaders from academia, medicine and industry. Chicago, UNITED STATES hosts the RSNA every year, which begins this year on the 27th (local time) and ends on the 1st of the following month.
Neurophet specializes in the development of diagnostic support solutions, treatment guides and treatment devices targeting brain diseases based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Jake Junkil Been, CEO, and Donghyeon Kim, CTO, who developed the next-generation neuro-navigation system.
The main products include “Neurophet AQUA” brain MRI imaging analysis and interpretation software, “Neurophet SCALE PET” brain PET (PET tracer deposition) analysis software, electrical stimulation simulation software and cerebral magnetic “Neurophet tES/TMS Lab”, and a brain region analysis tool of interest “Neurophet SegPlus”.
Neurophet has made it a top priority to help patients suffering from brain diseases. Based on its expertise in neuroscience, Neurophet will continue to challenge and grow to explore human brain health and pioneering solutions for brain disease with AI technology.
View original content to download multimedia: https://www.prnewswire.com/news-releases/neurophet-to-participate-in-the-radiological-society-of-north-america-rsna-2022-301687053.html
#Neurophet #participate #Radiological #Society #North #America #RSNA